Across TCGA pan-cancer cohorts, UBXN2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UBXN2B data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher UBXN2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBXN2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and LUSC are the cancer types where UBXN2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.209	0.541	.020	18	view →
UCEC	DFS	Median	All	0.953	0.623	.021	18	view →
LUSC	OS	Median	All	0.081	0.818	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: UBXN2B tumor-vs-normal RNA expression · all UBXN2B data types